A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors — Stella

Recruiting

Back to Urothelial Carcinoma Bladder trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United States

City of Hope, Duarte, California

Hoag Memorial Hospital Presbyterian, Irvine, California

Biogenix Molecular, LLC, Miami, Florida

University of Iowa, Iowa City, Iowa

United Theranostics, Glen Burnie, Maryland

Key details

Phase

Early testing

Sponsor

Aktis Oncology, Inc.

Enrollment target

~150 participants

Started

August 2025

Primary completion

December 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov